AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32588760 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-related prognostic signature constructed using 5 immune-associated genes (CXCL5, AZU1, NOD1, TNFRSF11B, VGF)
Number of subjects: 0
Study 32746950 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression group (instructed to suppress their emotions during the film)
Number of subjects: 82
Study 32746950 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression groups (both cultural backgrounds)
Number of subjects: 82
Study 32746950 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 32746950 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression group
Number of subjects: 82
Study 35853975 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with etomidate-remifentanil (ERD group)
Number of subjects: 180
Study 35853975 — intervention group
Group type: COMPARATOR
Intervention: Etomidate-remifentanil (ER group)
Number of subjects: 180
Study 33753363 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRATCH Trial (standard trial off HFNC)
Number of subjects: 271
Study 32014581 — intervention group
Group type: EXPERIMENTAL
Intervention: Violet LED (VL) irradiation for 30 min, twice per week for three weeks (totaling six sessions)
Number of subjects: 30
Study 32014581 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide (PC) without VL
Number of subjects: 30
Study 32014581 — intervention group
Group type: EXPERIMENTAL
Intervention: Violet LED (VL) irradiation
Number of subjects: 30
Study 35399071 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) group training, 8 sessions weekly (120-min/session) for 2 months
Number of subjects: 66
Study 35399071 — intervention group
Group type: COMPARATOR
Intervention: Menopausal health (control group)
Number of subjects: 66
Study 34419999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-Dep (polysomnography-monitored daytime sleep opportunity)
Number of subjects: 65
Study 34419999 — intervention group
Group type: COMPARATOR
Intervention: Sleep-Ctrl (daytime sleep)
Number of subjects: 65
Study 34419999 — intervention group
Group type: COMPARATOR
Intervention: Wake-Ctrl (stay awake)
Number of subjects: 65
Study 32839527 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 150 mg (twice daily)
Number of subjects: 20
Study 32839527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34987129 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg, bid)
Number of subjects: 80
Study 34987129 — intervention group
Group type: COMPARATOR
Intervention: Control (ACEI/ARB and β‐receptor blockers)
Number of subjects: 80
Study 32471730 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential wound retractor/protector (group B)
Number of subjects: 41
Study 32471730 — intervention group
Group type: COMPARATOR
Intervention: No circumferential wound retractor (group A)
Number of subjects: 41
Study 32471730 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative blood glucose levels below 200mg/dl
Number of subjects: 41
Study 35276312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternal-apical (SA) pad placement
Number of subjects: 484
Study 35276312 — intervention group
Group type: COMPARATOR
Intervention: Anterior-posterior (AP) pad placement
Number of subjects: 484
Study 33849138 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + music therapy for 60min
Number of subjects: 56
Study 33849138 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 34753303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 575
Study 34753303 — intervention group
Group type: COMPARATOR
Intervention: Control group (moderate/severe strokes)
Number of subjects: 575
Study 34753303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild strokes
Number of subjects: 575
Study 34753303 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual flow grade
Number of subjects: 575
Study 32278195 — intervention group
Group type: COMPARATOR
Intervention: Sham indoor air purification
Number of subjects: 29
Study 32278195 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered indoor air purification
Number of subjects: 29
Study 32278195 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal PM2.5 exposure
Number of subjects: 29
Study 35981956 — intervention group
Group type: EXPERIMENTAL
Intervention: so‐tDCS with individualized frequency
Number of subjects: 28
Study 35981956 — intervention group
Group type: COMPARATOR
Intervention: so‐tDCS with standardized frequency of 0.75 Hz
Number of subjects: 28
Study 35981956 — intervention group
Group type: EXPERIMENTAL
Intervention: stimulation trains of 30 seconds
Number of subjects: 28
Study 35981956 — intervention group
Group type: EXPERIMENTAL
Intervention: stimulation trains of 2 minutes and 5 minutes
Number of subjects: 28
Study 35664244 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC): UC plus personalized letter from physician, access to individualized GWG chart, ongoing counseling with RDN.
Number of subjects: 214
Study 35664244 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC): usual written educational materials and counseling by obstetric provider.
Number of subjects: 214
Study 36220809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-cue video exposure
Number of subjects: 47
Study 36220809 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 47
Study 36220809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-cues
Number of subjects: 47
Study 36220809 — intervention group
Group type: EXPERIMENTAL
Intervention: TSST followed by cocaine-cue video
Number of subjects: 47
Study 36220809 — intervention group
Group type: COMPARATOR
Intervention: TSST
Number of subjects: 47
Study 36220809 — intervention group
Group type: COMPARATOR
Intervention: Baseline ACTH levels
Number of subjects: 47
Study 33093340 — intervention group
Group type: EXPERIMENTAL
Intervention: Light group (cued by light on the PCA button)
Number of subjects: 125
Study 33093340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cues to medication availability)
Number of subjects: 125
Study 33093340 — intervention group
Group type: EXPERIMENTAL
Intervention: Light group
Number of subjects: 125
Study 33093340 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 32228168 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy (ABFT)
Number of subjects: 39
Study 32228168 — intervention group
Group type: COMPARATOR
Intervention: Non-responders to treatment
Number of subjects: 39
Study 32681402 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated medication recommendations
Number of subjects: 24
Study 34311713 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program (BLESS) with four follow-up contacts for exercise adherence
Number of subjects: 40
Study 34311713 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 34311713 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program (BLESS)
Number of subjects: 40
Study 33009542 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray Matters intervention (education and behavioral self-monitoring app)
Number of subjects: 146
Study 35957202 — intervention group
Group type: EXPERIMENTAL
Intervention: Five weeks of piano training
Number of subjects: 20
Study 35957202 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 35535379 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventing Hiesho: Intervention Program for Educating Nurses (2 weeks)
Number of subjects: 130
Study 35535379 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet on hiesho care
Number of subjects: 130
Study 36053828 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (test group)
Number of subjects: 158
Study 36053828 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 158
Study 32002565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA) for pulmonary vein isolation (PVI) and left atrial appendage closure (LAAC) device
Number of subjects: 27
Study 32002565 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC) device
Number of subjects: 27
Study 32171508 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir supplementation
Number of subjects: 28
Study 32171508 — intervention group
Group type: COMPARATOR
Intervention: Milk supplementation
Number of subjects: 28
Study 35427993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (AMP; n = 17)
Number of subjects: 30
Study 35427993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC; n = 11)
Number of subjects: 30
Study 35427993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AMP and PLAC)
Number of subjects: 30
Study 32952090 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning program (e-learning and on-site training)
Number of subjects: 60
Study 32000558 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physiotherapy with the workplace dialogue 'Convergence Dialogue Meeting' (CDM)
Number of subjects: 352
Study 32000558 — intervention group
Group type: COMPARATOR
Intervention: Structured physiotherapy
Number of subjects: 352
Study 36002562 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol prescribing or de-prescribing regimen
Number of subjects: 474
Study 36002562 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 474
Study 36002562 — intervention group
Group type: EXPERIMENTAL
Intervention: SICU participants
Number of subjects: 474
Study 36002562 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered level of consciousness (Feature 3)
Number of subjects: 474
Study 33998210 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC loaded with rhBMP‐2 combined with CPC loaded with antibiotic
Number of subjects: 80
Study 33998210 — intervention group
Group type: COMPARATOR
Intervention: CPC loaded with antibiotic
Number of subjects: 80
Study 32233554 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA disease signature
Number of subjects: 342
Study 33215209 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/day)
Number of subjects: 527
Study 33318110 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban health extension programme
Number of subjects: 744
Study 33318110 — intervention group
Group type: EXPERIMENTAL
Intervention: Divorced women
Number of subjects: 744
Study 33318110 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 45-53 years
Number of subjects: 744
Study 33318110 — intervention group
Group type: EXPERIMENTAL
Intervention: Private employees
Number of subjects: 744
Study 33318110 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsatisfactory knowledge
Number of subjects: 744
Study 33318110 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived accessibility of health extension workers
Number of subjects: 744
Study 35509099 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure
Number of subjects: 0
Study 35509099 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA) exposure
Number of subjects: 0
Study 33427317 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMA antibullying program with student lessons
Number of subjects: 3135
Study 33427317 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMA antibullying program without student lessons
Number of subjects: 3135
Study 33427317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3135
Study 32992159 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-glottis pushing
Number of subjects: 250
Study 32992159 — intervention group
Group type: COMPARATOR
Intervention: Closed-glottis pushing
Number of subjects: 250
Study 34789542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing fruit/sweet-flavoured e-liquid (blackcurrant, strawberry, vanilla, caramel)
Number of subjects: 84
Study 34789542 — intervention group
Group type: COMPARATOR
Intervention: Unflavoured e-liquid
Number of subjects: 84
Study 33412641 — intervention group
Group type: EXPERIMENTAL
Intervention: A1-UV aspheric intraocular lens (IOL) implantation
Number of subjects: 42
Study 33412641 — intervention group
Group type: COMPARATOR
Intervention: SN60WF type IOL implantation (Control)
Number of subjects: 42
Study 33412641 — intervention group
Group type: EXPERIMENTAL
Intervention: A1-UV aspheric IOL
Number of subjects: 42
Study 33412641 — intervention group
Group type: COMPARATOR
Intervention: SN60WF type IOL (Control)
Number of subjects: 42
Study 33412641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 32493662 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous magnesium infusion (10 mmol loading dose of magnesium sulphate followed by 3 mmol/h for up to 96 hours)
Number of subjects: 198
Study 32493662 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium infusion)
Number of subjects: 198
Study 32493662 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous magnesium infusion
Number of subjects: 198
Study 32493662 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 35209708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1092
Study 35209708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary diseases
Number of subjects: 1092
Study 35209708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular diseases (CVD)
Number of subjects: 1092
Study 35209708 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1092
Study 35209708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 1092
Study 35209708 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal diseases
Number of subjects: 1092
Study 34842831 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft white paraffin (SWP)
Number of subjects: 2
Study 34842831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 2
Study 34842831 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen peroxide (H2O2)
Number of subjects: 2
Study 34432203 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg/d, orally)
Number of subjects: 90
Study 34432203 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/d, orally)
Number of subjects: 90
Study 34432203 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang
Number of subjects: 90
Study 34432203 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 90
Study 34632426 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic azithromycin (1 g orally) once at baseline
Number of subjects: 27
Study 34632426 — intervention group
Group type: COMPARATOR
Intervention: No azithromycin (control group)
Number of subjects: 27
Study 34923216 — intervention group
Group type: EXPERIMENTAL
Intervention: WATSU therapy combined with land-based therapy
Number of subjects: 28
Study 34923216 — intervention group
Group type: COMPARATOR
Intervention: Land-based therapy (Control Group)
Number of subjects: 28
Study 32003822 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA (Lung Cancer Screening: Is It Right for Me?)
Number of subjects: 516
Study 32003822 — intervention group
Group type: COMPARATOR
Intervention: EDU (standard educational material)
Number of subjects: 516
Study 36113828 — intervention group
Group type: EXPERIMENTAL
Intervention: APCS score combined with stool DNA test
Number of subjects: 2842
Study 36113828 — intervention group
Group type: COMPARATOR
Intervention: APCS score combined with FIT
Number of subjects: 2842
Study 33926493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild recovered trajectory
Number of subjects: 224
Study 33926493 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe persistent symptoms trajectory
Number of subjects: 224
Study 33926493 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovered from severe symptoms trajectory
Number of subjects: 224
Study 33107945 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation combined with vein of Marshall ethanol infusion
Number of subjects: 350
Study 35900817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile diabetes self-care (MC)
Number of subjects: 269
Study 35900817 — intervention group
Group type: EXPERIMENTAL
Intervention: MC with personalized, bidirectional feedback from physicians (MPC)
Number of subjects: 269
Study 35900817 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 269
Study 35900817 — intervention group
Group type: EXPERIMENTAL
Intervention: iCareD system satisfaction
Number of subjects: 269
Study 34592949 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (BOSMIN® SOLUTION 0.1%, diluted to 0.02%)
Number of subjects: 197
Study 34592949 — intervention group
Group type: COMPARATOR
Intervention: Tramazoline (TRAMAZOLIN Nasal Solution 0.118%)
Number of subjects: 197
Study 34592949 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (E)
Number of subjects: 197
Study 34592949 — intervention group
Group type: COMPARATOR
Intervention: Tramazoline (T)
Number of subjects: 197
Study 35759281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for headache (8 sessions)
Number of subjects: 193
Study 35759281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for PTSD (12 sessions)
Number of subjects: 193
Study 35759281 — intervention group
Group type: COMPARATOR
Intervention: Treatment per usual (Control)
Number of subjects: 193
Study 33526042 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) Basic Life Support (BLS) course, 35 minutes duration
Number of subjects: 160
Study 33526042 — intervention group
Group type: COMPARATOR
Intervention: Classic BLS course with seminar and basic skill training
Number of subjects: 160
Study 33568368 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral melatonin nightly for 12 weeks
Number of subjects: 40
Study 33568368 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 12 weeks
Number of subjects: 40
Study 33568368 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral melatonin
Number of subjects: 40
Study 33023498 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-retroviral treatment (ART)
Number of subjects: 414
Study 33023498 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter duration of ART (≤2 years)
Number of subjects: 414
Study 33023498 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age (16-30 years)
Number of subjects: 414
Study 33023498 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 31-45 years
Number of subjects: 414
Study 33023498 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of ART at Health Center IV
Number of subjects: 414
Study 34846278 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic care given in line with Levine's Conservation Model (LCM)
Number of subjects: 80
Study 34846278 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 35426326 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) treatment
Number of subjects: 1736
Study 35426326 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1736
Study 34789700 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine injection
Number of subjects: 100
Study 34789700 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 100
Study 32801130 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10000
Study 32801130 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 10000
Study 32801130 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 10000
Study 36103386 — intervention group
Group type: COMPARATOR
Intervention: Alfaxalone (5 mg/kg, IV) + Physiologic saline (0.5 mL, IM)
Number of subjects: 72
Study 36103386 — intervention group
Group type: COMPARATOR
Intervention: Alfaxalone (5 mg/kg, IM) + Physiologic saline (0.5 mL, IM)
Number of subjects: 72
Study 36103386 — intervention group
Group type: COMPARATOR
Intervention: Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IV)
Number of subjects: 72
Study 36103386 — intervention group
Group type: COMPARATOR
Intervention: Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IM)
Number of subjects: 72
Study 36103386 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg, IM) + Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IV)
Number of subjects: 72
Study 36103386 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg, IM) + Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IM)
Number of subjects: 72
Study 36103386 — intervention group
Group type: COMPARATOR
Intervention: Medetomidine + Alfaxalone
Number of subjects: 72
Study 33308198 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored antihypertensive medication based on mean arterial pressure/heart rate ratio
Number of subjects: 208
Study 33308198 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological standard care according to national and international guidelines
Number of subjects: 208
Study 35708709 — intervention group
Group type: EXPERIMENTAL
Intervention: DDGP regimen (dexamethasone, cisplatin, gemcitabine, and pegaspargase)
Number of subjects: 80
Study 35708709 — intervention group
Group type: COMPARATOR
Intervention: SMILE regimen (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide)
Number of subjects: 80
Study 34407626 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry participants
Number of subjects: 2056
Study 34407626 — intervention group
Group type: COMPARATOR
Intervention: RCT
Number of subjects: 2056
Study 34407626 — intervention group
Group type: COMPARATOR
Intervention: Eligible patients for RCT
Number of subjects: 2056
Study 32491956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), 2 sessions applied to pain points with a 48-hr interval
Number of subjects: 20
Study 32491956 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, 2 sessions applied to pain points with a 48-hr interval
Number of subjects: 20
Study 34765467 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative early high-energy feeding
Number of subjects: 244
Study 32653721 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive video OOPP
Number of subjects: 94